¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º °¨½Ã ½ÃÀå
Antimicrobial Resistance Surveillance
»óǰÄÚµå : 1777785
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 377 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º °¨½Ã ½ÃÀåÀº 2030³â±îÁö 79¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 61¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Ç×»ýÁ¦ ³»¼º °¨½Ã ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 4.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 79¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Áø´Ü ŰƮ´Â CAGR 5.3%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 40¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áø´Ü ½Ã½ºÅÛ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 4.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 16¾ï ´Þ·¯, Áß±¹Àº CAGR 8.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ç×»ýÁ¦ ³»¼º °¨½Ã ½ÃÀåÀº 2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 17¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.4%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.8%¿Í 3.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º °¨½Ã ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

½´ÆÛ¹ö±× À§Çù Áõ°¡´Â AMR °¨½Ã¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

Ç×±ÕÁ¦ ³»¼º(AMR)Àº Àü ¼¼°è °øÁߺ¸°ÇÀÇ À§±âÀ̸ç, ¾àÁ¦ ³»¼º °¨¿°À» ¹æÄ¡ÇÒ °æ¿ì 2050³â±îÁö ¿¬°£ 1,000¸¸ ¸íÀÌ »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ´ÙÁ¦³»¼º(MDR) ¹ÚÅ׸®¾Æ, °õÆÎÀÌ, ¹ÙÀÌ·¯½º, ±â»ýÃæ Áõ°¡·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î °ß°íÇÑ AMR °¨½Ã ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ, ÀÇ·á ±â°ü, Á¦¾àȸ»ç´Â ³»¼º ÆÐÅÏÀ» ÃßÀûÇÏ°í ¿ÏÈ­Çϱâ À§ÇØ Á¶±â ¹ß°ß ¸ÞÄ¿´ÏÁò, À¯Àüü ½ÃÄö½Ì, ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ ¼¼°è Ç×±ÕÁ¦ ³»¼º ¹× »ç¿ë °¨½Ã ½Ã½ºÅÛ(Global Antimicrobial Resistance and Use Surveillance System, GLASS)Àº °¢±¹ÀÇ °¨½Ã Á¢±Ù¹ýÀ» Ç¥ÁØÈ­ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇØ¿Ô½À´Ï´Ù. ±×·¯³ª ¸¹Àº ÀúÀÚ¿ø ±¹°¡µéÀº µ¥ÀÌÅÍ ¼öÁý, °Ë»ç ÀÎÇÁ¶ó, Áø´Ü ´É·Â¿¡ ÀÖ¾î ¿©ÀüÈ÷ ¾î·Á¿òÀ» °Þ°í ÀÖÀ¸¸ç, AMR ÃßÀûÀ» °­È­Çϱâ À§ÇØ ¸ð¹ÙÀÏ ±â¹Ý ¹× AI¸¦ Ȱ¿ëÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù.

÷´Ü ±â¼úÀÌ AMR °¨½Ã¸¦ ÀçÁ¤ÀÇÇÒ ¼ö ÀÖÀ»±î?

Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®±â(NGS), ¸Ó½Å·¯´× ¾Ë°í¸®Áò, ºòµ¥ÀÌÅÍ ºÐ¼®ÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀº AMR °¨½ÃÀÇ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, ³»¼º º´¿øÃ¼¸¦ º¸´Ù ºü¸£°í Á¤È®ÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ¸ðµ¨Àº ÇöÀç ÀüÀÚÀǹ«±â·Ï(EHR)°ú ÅëÇյǾî AMRÀÇ ÃßÀ̸¦ ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾ú°í, ÀÓ»óÀǰ¡ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î Ä¡·á ¹æÄ§À» °áÁ¤ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå Áø´Ü ¹× ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­´Â ÀÓ»ó ¹× Áö¿ª»çȸ ȯ°æ ¸ðµÎ¿¡¼­ ³»¼º Á¶±â ¹ß°ßÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀº Àü ¼¼°è µ¥ÀÌÅÍ °øÀ¯¸¦ °¡´ÉÇÏ°Ô Çϰí, ±¹Á¦ Çù·ÂÀ» ÃËÁøÇϸç, AMR ¹ß»ý¿¡ ´ëÇÑ ´ëºñ¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. AMR µ¥ÀÌÅÍ °ü¸®¿¡ ºí·ÏüÀÎ ±â¼úÀ» µµÀÔÇÔÀ¸·Î½á Åõ¸í¼º°ú ½Å·Ú¼ºÀÌ Çâ»óµÇ°í, Ç×±ÕÁ¦ »ç¿ë·®°ú ³»¼º±ÕÀÇ ÁøÈ­¸¦ Á¤È®ÇÏ°Ô ÃßÀûÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù.

AMR °¨½Ã¸¦ Àü Áö¿ªÀ¸·Î È®´ëÇÏ´Â µ¥ À־ÀÇ °úÁ¦´Â?

ÀÌ·¯ÇÑ ¹ßÀü¿¡µµ ºÒ±¸ÇÏ°í ¸î °¡Áö À庮ÀÌ AMR °¨½ÃÀÇ ¼¼°è È®ÀåÀ» °¡·Î¸·°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÁßÀú¼Òµæ±¹°¡(LMICs)¿¡¼­´Â ÇÑÁ¤µÈ ÀÚ±Ý, ¼÷·ÃµÈ Àη ºÎÁ·, ±ÔÁ¦ °ÝÂ÷°¡ ¿©ÀüÈ÷ Å« ¹®Á¦ÀÔ´Ï´Ù. ¶ÇÇÑ, ½ÃÆÇ Ç×»ýÁ¦ ÆÇ¸Å, ÀÚ°¡ Ä¡·á, ºÒÃæºÐÇÑ º´¿ø °¨¿° °ü¸® Á¤Ã¥Àº ³»¼º±ÕÀÇ Á¶¿ëÇÑ È®»êÀ» Á¶ÀåÇÏ°í °¨½Ã Ȱµ¿À» ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. °¡Ãà ¹× ½Äǰ °ø±Þ¸Á¿¡¼­ Àμö°øÅëÀü¿°º´(AMR) º´¿øÃ¼ÀÇ Á¸Àç°¡ Áõ°¡ÇÔ¿¡ µû¶ó Àΰ£, µ¿¹°, ȯ°æ °¨½Ã¸¦ ÅëÇÕÇÏ´Â º¸´Ù °­·ÂÇÑ ¿øÇコ Á¢±Ù¹ýÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î AMR¿¡ È¿°úÀûÀ¸·Î ´ëÀÀÇϱâ À§Çؼ­´Â ÅëÀÏµÈ º¸°í ±âÁØ, ½Ç½Ã°£ µ¥ÀÌÅÍ Á¢±Ù, Á¤ºÎ ±â°ü°ú ¹Î°£ ÀÇ·á±â°üÀÇ Çù·Â ü°è°¡ ÇʼöÀûÀÔ´Ï´Ù.

Ç×±ÕÁ¦ ³»¼º °¨½Ã ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Ç×±ÕÁ¦ ³»¼º °¨½Ã ½ÃÀåÀÇ ¼ºÀåÀº ¾àÁ¦ ³»¼º °¨¿°ÀÇ ºÎ´ã Áõ°¡, À¯Àüü ½ÃÄö½Ì ±â¼ú äÅà Áõ°¡, Á¤ºÎ ÁÖµµÀÇ °¨½Ã ÀÌ´Ï¼ÅÆ¼ºê µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁú °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¦¾à¾÷°è´Â µ¿¹Ý Áø´Ü ¹× ³»¼º ÇÁ·ÎÆÄÀϸµ µµ±¸¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖÀ¸¸ç, Â÷¼¼´ë Ç×»ýÁ¦ ¹× ´ëü ¿ä¹ý °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. AI ÅëÇÕ ¸ð´ÏÅ͸µ Ç÷§Æû, ¿¹Ãø ºÐ¼®, ºí·ÏüÀÎ ±â¹Ý ÃßÀû ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥°ú ½Ç½Ã°£ AMR º¸°í¸¦ Àǹ«È­ÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ÁöħÀÌ °¨½Ã ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á, ½Å¼ÓÁø´Ü°Ë»ç, ¿øÇコ ÇÁ·¹ÀÓ¿öÅ©¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó AMR °¨½Ã ½ÃÀåÀ» Áö¼ÓÀûÀ¸·Î °ßÀÎÇÒ °ÍÀ̸ç, Ç×±ÕÁ¦ ³»¼º°úÀÇ ½Î¿ò¿¡ ÀÖ¾î Ãʼ®À¸·Î ÀÚ¸®¸Å±èÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

¼Ö·ç¼Ç(Áø´Ü ŰƮ, Áø´Ü ½Ã½ºÅÛ, Áø´Ü ¼ÒÇÁÆ®¿þ¾î, Áø´Ü ¼­ºñ½º), ¿ëµµ(ÀÓ»ó Áø´Ü ¿ëµµ, °øÁßÀ§»ý °¨½Ã ¿ëµµ, ½ÇÇè½Ç °¨½Ã ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø, Áø·á¼Ò, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Antimicrobial Resistance Surveillance Market to Reach US$7.9 Billion by 2030

The global market for Antimicrobial Resistance Surveillance estimated at US$6.1 Billion in the year 2024, is expected to reach US$7.9 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Diagnostic Kits, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Diagnostic Systems segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.4% CAGR

The Antimicrobial Resistance Surveillance market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Antimicrobial Resistance Surveillance Market - Key Trends & Drivers Summarized

How Is the Growing Threat of Superbugs Shaping AMR Surveillance?

Antimicrobial resistance (AMR) is a global public health crisis, with drug-resistant infections projected to cause 10 million deaths annually by 2050 if left unchecked. The increasing prevalence of multi-drug resistant (MDR) bacteria, fungi, viruses, and parasites has accelerated the demand for robust AMR surveillance systems worldwide. Governments, healthcare institutions, and pharmaceutical companies are investing in early detection mechanisms, genome sequencing, and real-time data analytics to track and mitigate resistance patterns. The World Health Organization’s Global Antimicrobial Resistance and Use Surveillance System (GLASS) has been pivotal in standardizing surveillance approaches across nations. However, many low-resource countries still face challenges in data collection, laboratory infrastructure, and diagnostic capabilities, necessitating innovative mobile-based and AI-powered solutions to enhance AMR tracking.

Can Cutting-Edge Technologies Redefine AMR Surveillance?

The rapid advancements in next-generation sequencing (NGS), machine learning algorithms, and big data analytics have revolutionized AMR surveillance, allowing for faster and more precise identification of resistant pathogens. AI-driven predictive models are now being integrated with electronic health records (EHRs) to track AMR trends in real-time, helping clinicians make informed treatment decisions. Moreover, point-of-care diagnostics and wearable biosensors are improving early resistance detection in both clinical and community settings. Cloud-based platforms enable global data sharing, fostering international collaborations and reinforcing preparedness against AMR outbreaks. The introduction of blockchain technology in AMR data management is also enhancing transparency and reliability, ensuring accurate tracking of antimicrobial usage and resistance evolution.

What Are the Challenges in Expanding AMR Surveillance to All Regions?

Despite advancements, several barriers hinder the global expansion of AMR surveillance. Limited funding, lack of skilled personnel, and regulatory disparities remain major challenges, particularly in low- and middle-income countries (LMICs). Additionally, over-the-counter antibiotic sales, self-medication practices, and poor hospital infection control policies contribute to the silent spread of resistance, making surveillance efforts more complex. The growing presence of zoonotic AMR pathogens in livestock and food supply chains demands stronger One Health approaches, integrating human, animal, and environmental surveillance under a unified system. Ensuring uniform reporting standards, real-time data access, and collaboration between government agencies and private healthcare providers is imperative for tackling AMR effectively on a global scale.

What’s Fueling the Growth of the Antimicrobial Resistance Surveillance Market?

The growth in the antimicrobial resistance surveillance market is driven by several factors, including the rising burden of drug-resistant infections, increasing adoption of genomic sequencing technologies, and government-led surveillance initiatives. The pharmaceutical industry is actively investing in companion diagnostics and resistance profiling tools, fostering the development of next-generation antibiotics and alternative therapies. The increasing demand for AI-integrated surveillance platforms, predictive analytics, and blockchain-based tracking systems is further bolstering market expansion. Moreover, stringent regulatory guidelines mandating antibiotic stewardship programs and real-time AMR reporting are propelling investments in surveillance infrastructure. The growing focus on precision medicine, rapid diagnostic tests, and One Health frameworks will continue to drive the AMR surveillance market, positioning it as a cornerstone in the global fight against antimicrobial resistance.

SCOPE OF STUDY:

The report analyzes the Antimicrobial Resistance Surveillance market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Solution (Diagnostic Kits, Diagnostic Systems, Diagnostics Software, Diagnostic Services); Application (Clinical Diagnostics Application, Public Health Surveillance Application, Laboratory Surveillance Application); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â